Clin Pharmacol Ther. 2013 Mar 18. doi: 10.1038/clpt.2013.57. [Epub ahead of print]
Biomarkers for Smoking Cessation.
Bough KJ, Lerman C, Rose JE, McClernon FJ, Kenny PJ, Tyndale RF, David SP, Stein EA, Uhl GR, Conti DV, Green C, Amur S.
Division of Pharmacotherapies and Medical Consequences, National Institute on Drug Abuse, Bethesda, Maryland, USA.
One way to enhance therapeutic development is through the identification and development of evaluative tools such as biomarkers. This review focuses on putative diagnostic, pharmacodynamic, and predictive biomarkers for smoking cessation. These types of biomarkers may be used to more accurately diagnose a disease, personalize treatment, identify novel targets for drug discovery, and enhance the efficiency of drug development. Promising biomarkers are presented across a range of approaches including metabolism, genetics, and neuroimaging. A preclinical viewpoint is also offered, as are analytical considerations and a regulatory perspective summarizing a pathway toward biomarker qualification.Clinical Pharmacology & Therapeutics (2013); advance online publication 8 May 2013. doi:10.1038/clpt.2013.57.
- [PubMed - as supplied by publisher]